Alumis Inc.

Contributing Author

Recent Articles by Alumis Inc.

Jul-24	Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus ALMS GlobeNewswire
Jul-14	Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary ALMS GlobeNewswire
May-29	Alumis to Present at the Jefferies Global Healthcare Investor Conference ALMS GlobeNewswire
May-29	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis ALMS GlobeNewswire
May-21	Alumis Completes Merger with ACELYRIN ALMS GlobeNewswire
May-14	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements ALMS GlobeNewswire
May-13	Alumis Stockholders Approve Merger with ACELYRIN ALMS GlobeNewswire